Anjali Singh

Anjali Singh

Anjali Singh covers the automobile and pharmaceutical sectors, focusing on trends, policy developments, regulatory changes, industry expectations, corporate results among others. A postgraduate in communication journalism, she has a strong inclination towards data-driven reporting and enjoys breaking down complex topics to make them interesting and relevant for readers.

Email
Twitter
LinkedIn

Anjali Singh

Royal Enfield posted record quarterly sales of 3.77 lakh motorcycles, while Eicher Motors reported a 15 per cent rise in Q2 profit and plans to ramp up production amid demand

Updated On: 13 Nov 2026 | 7:47 PM IST

Passenger vehicle sales rose 12.4 per cent to a record 519,060 units in October, while two-wheeler sales grew 16.1 per cent and three-wheeler sales climbed 25.7 per cent

Updated On: 13 Nov 2026 | 4:25 PM IST

Following a US FDA warning over a rare vision-loss condition, specialists say the absolute risk remains low, while the metabolic and cardiovascular benefits of GLP-1 drugs are substantial

Updated On: 12 Nov 2026 | 10:40 PM IST

The drugmaker expects around 40 per cent US growth in FY27 despite the end of Bosutinib exclusivity, while focusing on complex generics and improving domestic sales productivity

Updated On: 11 Nov 2026 | 11:27 PM IST

Strong festive sales lift sentiment, but a high base, uneven rural recovery and widening gap between premium and entry-level models may weigh on two-wheeler growth in H2 FY27

Updated On: 11 Nov 2026 | 11:15 PM IST

Global review covering over 200 million participant observations links prolonged PM2.5 exposure to higher Type 2 diabetes risk, highlighting metabolic health concerns in polluted regions

Updated On: 11 Nov 2026 | 8:44 PM IST

Ceat, JK Tyre, and Apollo Tyres signal further price hikes as surging rubber and crude-linked costs continue to squeeze margins

Updated On: 10 Nov 2026 | 12:32 AM IST

The hospital chain reported revenue of ₹2,829 crore in Q2FY27, driven by higher patient volumes, improved occupancy, complex procedures and growth in medical value travel

Updated On: 06 Nov 2026 | 7:28 PM IST

Auto business profit jumped 55 per cent as revenue grew 39 per cent, while the farm business saw lower sales and profitability amid a festive-season shift and margin pressure

Updated On: 05 Nov 2026 | 11:44 PM IST

Maharashtra secured investment commitments worth ₹8.57 trillion through 67 agreements in October, but land acquisition and power costs could slow their conversion into projects.

Updated On: 05 Nov 2026 | 11:26 PM IST

Consolidated revenue declined 29.8 per cent to ₹4,247 crore from ₹6,047 crore in Q2FY26

Updated On: 05 Nov 2026 | 8:28 PM IST

Biocon's Q2FY27 net profit fell 52 per cent to ₹41 crore as delayed shipments worth $20 million hit margins, while revenue rose 2 per cent to ₹4,389 crore.

Updated On: 04 Nov 2026 | 11:41 PM IST

Hyderabad-based HRV Pharma acquires German clinical trial supplier Phatebo, which reported ₹350 crore revenue in 2025, marking its entry into Europe's finished formulations business

Updated On: 03 Nov 2026 | 6:49 PM IST

Emcure Pharmaceuticals reports 24.2 per cent revenue growth in Q2FY27, led by strong international sales, while domestic business expands 12 per cent and net profit rises 33.7 per cent

Updated On: 03 Nov 2026 | 6:16 PM IST

The tentative approval for generic lenacapavir is expected to accelerate affordable access to the twice-yearly HIV prevention injection across 120 countries outside the US.

Updated On: 02 Nov 2026 | 9:06 PM IST

Syngene International expects a stronger second half of FY27, driven by its order book and Zoetis supplies, while retaining guidance for a single-digit revenue decline.

Updated On: 01 Nov 2026 | 8:30 PM IST

Exceptional charges of Rs 1,268.8 crore, including a US antitrust settlement and Organon acquisition costs, weighed on profit, while India formulation sales grew 17.3 per cent

Updated On: 30 Oct 2026 | 11:46 PM IST

At the BFSI Insight Summit 2026, industry leaders said digital platforms, innovative SIP products, investor education and AI tools could help expand India's mutual fund base to 200 million.

Updated On: 28 Oct 2026 | 10:47 PM IST

The company attributed the decline primarily to lower lenalidomide sales in North America. The base business, excluding lenalidomide in North America, continued to deliver double-digit growth

Updated On: 24 Oct 2026 | 12:34 AM IST

Next phase of growth hinges on biologics, peptides, and drug-device combinations, say industry executives

Updated On: 23 Oct 2026 | 6:41 AM IST